Valuation: Femasys Inc.

Market Cap 6.91M 5.97M 5.61M 5.1M 9.6M 661M 9.75M 65.76M 25.71M 331M 25.96M 25.4M 1.1B P/E 2026 *
-0.46x
P/E 2027 * -0.39x
Enterprise Value 6.91M 5.97M 5.61M 5.1M 9.6M 661M 9.75M 65.76M 25.71M 331M 25.96M 25.4M 1.1B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 0.69x
Free-Float
95.97%
Yield 2026 *
-
Yield 2027 * -
1 week-13.91%
Current month-19.93%
1 month-24.92%
3 months-67.89%
6 months-77.47%
Current year-80.13%
1 week 2.19
Extreme 2.19
2.6
1 month 2.19
Extreme 2.19
4.22
Current year 2.19
Extreme 2.19
14.51
1 year 2.19
Extreme 2.19
22.2
3 years 2.19
Extreme 2.19
95
5 years 2.19
Extreme 2.19
167.99
10 years 2.19
Extreme 2.19
275
Manager TitleAgeSince
Chief Executive Officer 58 31/12/2003
Director of Finance/CFO 58 27/02/2022
Chief Operating Officer 52 29/03/2026
Director TitleAgeSince
Chairman 58 31/12/2003
Chairman 74 05/07/2022
Director/Board Member 75 31/07/2005
Date Insider Type Main position Quantity % Market Cap.
07/08/26 Buy

Chief Technology Officer

9,375 0.3105%
07/08/26 Buy

Chief Financial Officer

46,875 1.5524%
07/08/26 Buy

Founder

46,875 1.5524%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-13.91%-83.88%-71.38% 6.91M
-0.02%+3.19%-15.56%+6.43% 193B
+0.76%+4.72%-1.88%+11.89% 117B
+1.43%-2.07%+7.17%+70.56% 59.89B
-0.92%+0.57%+34.56%+70.98% 56.01B
+0.79%+3.70%-6.40%-33.73% 49.96B
-1.89%+5.90%+10.87%-19.26% 33.87B
+0.45%+1.45% - - 31.36B
-1.96%+1.73%-6.04%+27.56% 24.77B
+0.94%-1.31%+41.93%-12.09% 24.59B
Average -0.04%+1.82%-2.14%+5.66% 58.98B
Weighted average by Cap. +0.14%+3.34%+0.14%+15.89%

Financials

2026 *2027 *
Net sales 3.77M 3.25M 3.06M 2.78M 5.23M 360M 5.31M 35.82M 14M 180M 14.14M 13.83M 599M 10M 8.64M 8.12M 7.38M 13.88M 956M 14.11M 95.12M 37.19M 479M 37.55M 36.74M 1.59B
Net income -16.22M -14.01M -13.16M -11.97M -22.51M -1.55B -22.88M -154M -60.31M -777M -60.89M -59.57M -2.58B -21.29M -18.38M -17.28M -15.71M -29.54M -2.04B -30.03M -202M -79.14M -1.02B -79.92M -78.18M -3.39B
Net Debt - -
Logo Femasys Inc.
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Employees
53
Date Price Change Volume
14/08/26 US$2.290 0.00% 117,251
13/08/26 US$2.290 -2.55% 154,879
12/08/26 US$2.350 0.00% 701,257
11/08/26 US$2.350 -0.84% 240,354
10/08/26 US$2.370 -10.90% 400,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.290USD
Average target price
56.67USD
Spread / Average Target
+2,374.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FEMY Stock